Sensorion SA (ALSEN.PA)
EUR 0.64
(-6.16%)
EUR 0.64
(-6.16%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.74 Million EUR | -3.86% |
| 2022 | 4.93 Million EUR | 15.71% |
| 2021 | 4.26 Million EUR | 81.27% |
| 2020 | 2.35 Million EUR | -4.26% |
| 2019 | 2.45 Million EUR | 10.14% |
| 2018 | 2.23 Million EUR | 15.3% |
| 2017 | 1.93 Million EUR | 10954.01% |
| 2016 | 17.5 Thousand EUR | -88.89% |
| 2015 | 157.51 Thousand EUR | -31.98% |
| 2014 | 231.56 Thousand EUR | -35.05% |
| 2013 | 356.53 Thousand EUR | 53.88% |
| 2012 | 231.69 Thousand EUR | 1103200.0% |
| 2011 | 21.00 EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 3.13 Million EUR | 0.0% |
| 2023 Q2 | 2.55 Million EUR | 0.0% |
| 2023 Q4 | 3.01 Million EUR | 0.0% |
| 2023 FY | 4.74 Million EUR | -3.86% |
| 2022 Q2 | 1.89 Million EUR | 0.0% |
| 2022 FY | 4.93 Million EUR | 15.71% |
| 2022 Q4 | 3.04 Million EUR | 0.0% |
| 2021 Q2 | 1.55 Million EUR | 0.0% |
| 2021 Q4 | 2.71 Million EUR | 0.0% |
| 2021 FY | 4.26 Million EUR | 81.27% |
| 2020 Q4 | 1.47 Million EUR | 0.0% |
| 2020 Q2 | 872.5 Thousand EUR | 0.0% |
| 2020 FY | 2.35 Million EUR | -4.26% |
| 2019 Q2 | 1.04 Million EUR | 0.0% |
| 2019 FY | 2.45 Million EUR | 10.14% |
| 2019 Q4 | 1.41 Million EUR | 0.0% |
| 2018 Q2 | 1.25 Million EUR | 0.0% |
| 2018 Q4 | 971.58 Thousand EUR | 0.0% |
| 2018 FY | 2.23 Million EUR | 15.3% |
| 2017 FY | 1.93 Million EUR | 10954.01% |
| 2017 Q4 | 886.98 Thousand EUR | 0.0% |
| 2017 Q2 | 1.04 Million EUR | 0.0% |
| 2016 FY | 17.5 Thousand EUR | -88.89% |
| 2016 Q2 | 1.08 Million EUR | 0.0% |
| 2016 Q4 | -1.06 Million EUR | 0.0% |
| 2015 FY | 157.51 Thousand EUR | -31.98% |
| 2015 Q4 | -292.43 Thousand EUR | 0.0% |
| 2015 Q2 | 449.94 Thousand EUR | 0.0% |
| 2014 FY | 231.56 Thousand EUR | -35.05% |
| 2014 Q4 | 8376.00 EUR | 0.0% |
| 2014 Q3 | - EUR | -100.0% |
| 2014 Q2 | 223.87 Thousand EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 FY | 356.53 Thousand EUR | 53.88% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 FY | 231.69 Thousand EUR | 1103200.0% |
| 2012 Q1 | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q3 | - EUR | 0.0% |
| 2011 FY | 21.00 EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -2.221% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -2.642% |
| Adocia SA | 2.15 Million EUR | -120.608% |
| Aelis Farma SA | 9.05 Million EUR | 47.614% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -50.526% |
| genOway Société anonyme | 20.04 Million EUR | 76.34% |
| IntegraGen SA | 12.53 Million EUR | 62.169% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -1480.842% |
| Neovacs S.A. | 533.41 Thousand EUR | -789.193% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -182.071% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -23859.709% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -1500.597% |
| TME Pharma N.V. | 17 Thousand EUR | -27800.376% |
| Valbiotis SA | 4.73 Million EUR | -0.213% |
| TheraVet SA | 1.07 Million EUR | -339.965% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -163.504% |
| argenx SE | 1.13 Billion EUR | 99.582% |
| BioSenic S.A. | 543 Thousand EUR | -773.492% |
| Celyad Oncology SA | 102 Thousand EUR | -4550.063% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 98.021% |
| Genfit S.A. | 28.56 Million EUR | 83.396% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -127.267% |
| Innate Pharma S.A. | 51.9 Million EUR | 90.861% |
| Inventiva S.A. | 17.47 Million EUR | 72.861% |
| MaaT Pharma SA | 2.22 Million EUR | -112.884% |
| MedinCell S.A. | 9.16 Million EUR | 48.22% |
| Nanobiotix S.A. | 30.05 Million EUR | 84.22% |
| Onward Medical N.V. | 532 Thousand EUR | -791.553% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 66.578% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -112.98% |
| Oxurion NV | 263 Thousand EUR | -1703.446% |
| Pharming Group N.V. | 245.31 Million EUR | 98.067% |
| Poxel S.A. | 1.98 Million EUR | -139.428% |
| GenSight Biologics S.A. | 1.26 Million EUR | -274.354% |
| Transgene SA | 1.18 Million EUR | -300.597% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.91% |
| Valneva SE | 153.71 Million EUR | 96.914% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 231.024% |